Sidoplus5 mg+50 mg

Sidoplus is a fixed-dose combination antihypertensive indicated for the treatment of hypertension in patients who require combination therapy for adequate blood pressure control, typically when blood pressure is not adequately controlled on either component alone.

Established / Guideline-Supported Uses

• Essential hypertension requiring combination therapy — first-line component combination endorsed by major hypertension guidelines when a calcium channel blocker plus a beta-blocker approach is appropriate.
• Hypertension with co-existing stable angina pectoris — the combination provides both anti-anginal and antihypertensive benefit, since amlodipine and atenolol are each individually indicated for angina.

Adjunct / Additional Uses (component-level evidence)

• In patients with a prior myocardial infarction who also have hypertension and/or angina, the beta-blocker component (atenolol) contributes secondary cardiovascular risk reduction, though this is an extension of the individual component's evidence rather than a primary indication for the fixed combination itself.

Sidoplus is not intended as initial single-agent therapy for patients who have not first been tried on, or found intolerant to, monotherapy, unless the treating physician determines combination therapy is appropriate from the outset based on the degree of blood pressure elevation.

Amlodipine + Atenolol is a fixed-dose combination of two active ingredients:

• Amlodipine (as amlodipine besylate/besilate) — a dihydropyridine calcium channel blocker.
• Atenolol — a beta-1 selective (cardioselective) adrenergic receptor blocking agent.

Common marketed strengths include amlodipine 5 mg with atenolol 25 mg, and amlodipine 5 mg with atenolol 50 mg, supplied as oral tablets.

Sidoplus combines two antihypertensive agents with complementary mechanisms of action in a single tablet. This combination is used when a patient's blood pressure is not adequately controlled by either agent alone, or when the physician determines that initiating combination therapy is clinically appropriate.

By combining a vasodilating calcium channel blocker with a heart-rate-lowering beta-blocker, Sidoplus addresses blood pressure elevation through two distinct physiological pathways, which can improve overall blood pressure control while allowing lower doses of each individual component than might otherwise be needed.

Sidoplus belongs to the therapeutic class of combination antihypertensive agents, specifically a calcium channel blocker (dihydropyridine) combined with a beta-1 selective adrenergic blocker.

Amlodipine + Atenolol works through two complementary antihypertensive mechanisms:

• Amlodipine is a dihydropyridine calcium channel blocker. It inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Its primary action is on vascular smooth muscle, producing peripheral arterial vasodilation and a resultant reduction in peripheral vascular resistance and blood pressure.
• Atenolol is a beta-1 selective (cardioselective) adrenergic receptor blocking agent. It reduces heart rate, myocardial contractility, and cardiac output, and suppresses renin release, all of which contribute to a reduction in blood pressure and myocardial oxygen demand.

Used together in Amlodipine + Atenolol, vasodilation from the calcium channel blocker component is complemented by heart-rate and cardiac-output reduction from the beta-blocker component, providing an additive antihypertensive effect through two distinct mechanisms.

Pharmacokinetics (brief): Amlodipine is slowly and almost completely absorbed orally, is highly protein-bound, and is extensively hepatically metabolized with a long elimination half-life (approximately 30-50 hours) allowing once-daily dosing. Atenolol is incompletely absorbed orally (~50%), is only minimally metabolized, is predominantly renally excreted largely unchanged, and has a shorter half-life (approximately 6-7 hours), which requires dose adjustment in renal impairment.

Sidoplus tablets should be swallowed whole with a glass of water, once daily at approximately the same time each day, with or without food. Missed doses should not be doubled up; the next dose should simply be taken at the usual time. Sidoplus should not be discontinued suddenly without medical advice.

Sidoplus has clinically significant interactions relevant to both of its components:

• Other CYP3A4 inhibitors/inducers (e.g., strong CYP3A4 inhibitors such as itraconazole, ritonavir): may increase amlodipine plasma levels and the risk of hypotension and edema.
• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem): concomitant use with the atenolol component of Sidoplus can cause additive negative effects on heart rate and AV conduction, risking severe bradycardia or heart block.
• Other antihypertensives, nitrates, and PDE-5 inhibitors (e.g., sildenafil): additive blood-pressure-lowering effect with Sidoplus, increasing risk of symptomatic hypotension.
• Clonidine: the beta-blocker component of Sidoplus can worsen rebound hypertension if clonidine is withdrawn while a patient is on Sidoplus; if both must be stopped, the beta-blocker component's effect should be tapered off first and clonidine discontinued later, under physician supervision.
• Digoxin and other agents that slow AV conduction: additive bradycardic effect with the atenolol component, requiring monitoring of heart rate.
• NSAIDs: may reduce the antihypertensive effect of Sidoplus and can impair renal function, particularly in volume-depleted or elderly patients.
• Insulin and oral antidiabetic agents: the beta-blocker component of Sidoplus can mask the tachycardia that normally signals hypoglycemia, so diabetic patients should be monitored closely.
• Grapefruit juice: may increase amlodipine bioavailability; patients on Sidoplus should use caution with large quantities.

Most patients tolerate Sidoplus well. Reported adverse effects reflect both components:

Common

• Peripheral edema (ankle/leg swelling) — from the amlodipine component
• Fatigue and tiredness — from the atenolol component
• Bradycardia (slow heart rate)
• Dizziness, headache
• Cold extremities
• Flushing, palpitations
• Nausea, abdominal discomfort

Less Common / Serious

• Symptomatic hypotension
• Worsening of heart failure symptoms in susceptible patients
• Bronchospasm (particularly in patients with reactive airway disease)
• Mood changes, depression, sleep disturbances
• Masked symptoms of hypoglycemia in diabetics (see Interactions)

Patients should seek prompt medical advice for severe dizziness, fainting, very slow heart rate, marked swelling, or breathing difficulty while taking Sidoplus.

Pregnancy: Sidoplus should be used during pregnancy only if clearly needed and only under specialist guidance, and only if the potential benefit to the mother justifies the potential risk to the fetus. The atenolol component in particular has been associated with fetal growth restriction (small-for-gestational-age infants), and with neonatal bradycardia and hypoglycemia when used, especially with prolonged use later in pregnancy; alternative antihypertensive agents with a better-established safety profile in pregnancy are often preferred. A physician should be consulted before continuing or starting Sidoplus in pregnancy, and its use requires close fetal and maternal monitoring if continued.

Lactation: Both amlodipine and atenolol pass into breast milk, and atenolol may accumulate to relatively higher concentrations in milk than in maternal plasma, with a risk of bradycardia and hypoglycemia in the nursing infant. Breastfeeding while taking Sidoplus is generally not recommended unless a physician determines the benefit outweighs the risk; if breastfeeding is undertaken, the infant should be monitored closely.

• Do not stop abruptly: Because of the beta-blocker component, Sidoplus must not be discontinued suddenly, as this can precipitate rebound angina, myocardial infarction, ventricular arrhythmia, or rebound hypertension, especially in patients with underlying coronary artery disease. Dose should be tapered gradually under physician supervision.
• Heart failure: Use with caution in patients with compensated heart failure or reduced left ventricular function; the beta-blocker component can precipitate decompensation in susceptible patients.
• Bradycardia/AV conduction: Use with caution in patients with first-degree AV block or bradyarrhythmias, and monitor heart rate.
• Peripheral vascular disease: The beta-blocker component may aggravate symptoms of peripheral arterial insufficiency (e.g., Raynaud's phenomenon, intermittent claudication).
• Diabetes: May mask the tachycardia and tremor that are early warning signs of hypoglycemia; blood glucose should be monitored closely.
• Bronchospastic disease: Use with caution (or avoid) in patients with a history of asthma or COPD; beta-1 selectivity reduces but does not eliminate the risk of bronchospasm.
• Thyrotoxicosis: Beta-blockade may mask signs of hyperthyroidism (e.g., tachycardia); abrupt withdrawal could precipitate thyroid storm.
• Perioperative use: Anesthesiologists should be informed the patient is taking Sidoplus, as the beta-blocker component affects the response to anesthesia and surgical stress.
• Hepatic/renal impairment: Dose adjustment and close monitoring are required (see Dosage and Administration).
• Driving/operating machinery: Sidoplus may cause dizziness or fatigue, particularly when starting treatment; patients should exercise caution until they know how they respond.

Overdose of Sidoplus may cause pronounced hypotension, marked bradycardia, cardiac conduction disturbances, heart failure, dizziness, and in severe cases, cardiogenic shock or cardiac arrest. Excessive peripheral vasodilation from the amlodipine component combined with excessive negative chronotropic/inotropic effects from the atenolol component can produce profound and prolonged cardiovascular compromise.

Suspected overdose of Sidoplus is a medical emergency. Seek immediate medical attention or contact a poison control center/emergency services without delay. Do not attempt to manage an overdose at home; treatment requires hospital-based cardiovascular monitoring and supportive care under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Sidoplus can generally be used in elderly patients, but they may be more sensitive to blood-pressure-lowering and heart-rate-lowering effects; a lower starting dose and careful monitoring for hypotension, bradycardia, and dizziness/falls risk are advised.
• Renal impairment: Dose reduction of Sidoplus is required due to the atenolol component's renal elimination (see Dosage and Administration); close monitoring is advised, and use in severe renal impairment should be guided by a specialist.
• Hepatic impairment: Lower starting dose and slower titration of Sidoplus advised due to the amlodipine component's hepatic metabolism; monitor closely.
• Pediatric patients: Safety and efficacy of Sidoplus have not been established in children; not recommended for pediatric use (see Pediatric Uses).
• Pregnancy and lactation: See Pregnancy and Lactation section.
• Diabetic patients: Use with caution; the beta-blocker component of Sidoplus can mask signs of hypoglycemia (see Precautions and Warnings).

Sidoplus is typically used as long-term, ongoing therapy for chronic hypertension management, since hypertension generally requires indefinite treatment for cardiovascular risk reduction. Duration should be determined by the treating physician based on blood pressure control and tolerability, with periodic review. Sidoplus should not be stopped abruptly even if blood pressure has normalized, without medical guidance on tapering.

Combination antihypertensive: dihydropyridine calcium channel blocker + beta-1 selective (cardioselective) adrenergic blocker.

Amlodipine + Atenolol lowers blood pressure via two complementary mechanisms: the amlodipine component blocks L-type calcium channels in vascular smooth muscle, causing arterial vasodilation and reduced peripheral resistance; the atenolol component selectively blocks beta-1 adrenergic receptors, primarily in the heart, reducing heart rate, myocardial contractility, cardiac output, and renin release. Together these mechanisms produce an additive antihypertensive effect.

Safety and efficacy of Sidoplus have not been established in pediatric patients. This fixed-dose combination is not recommended for use in children or adolescents. If antihypertensive therapy is required in a pediatric patient, a physician should select an agent with established pediatric dosing and safety data, and combination therapy with Sidoplus should only be considered, if ever, under specialist pediatric cardiology/nephrology guidance.